Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Chinese Traditional Patent Medicine ; (12): 2072-2076, 2017.
Artigo em Chinês | WPRIM | ID: wpr-660568

RESUMO

AIM To establish an HPLC method for the simultaneous content determination of six constituents in Tibetan medicine Qishiwei Zhenzhu Pills (Croci Stigma,Dalbergiae odoriferae Lignum,Glycyrrhizae Radix et Rhizoma,etc.).METHODS The analysis of 50% methanol extract of this drug was carried out on a 30 ℃ thermostatic Inertsil(C)ODS-3 column (250 mm ×4.6 mm,5 μm),with the mobile phase comprising of 0.2% phosphoric acid-acetonitrile flowing at 0.8 mL/min in a gradient elution manner,and the detection wavelength was set at 254 nm.RESULTS Gallic acid,corilagin,agarotetrol,ellagic acid,crocin Ⅰ and crocin Ⅱ showed good linear relationships within the ranges of 1.41-42.24,0.61-18.24,0.30-9.12,0.47-14.04,0.62-18.48 and 0.32-9.45 μg/mL (R2 ≥0.999 4),whose average recoveries (RSDs) were 93.41% (1.75%),96.84% (1.75%),97.45% (0.58%),93.22% (0.56%),97.01% (1.39%) and 97.22% (1.11%),respectively.The contents of various constituents in different batches of samples from two manufactures showed some differences,especially for those of corilagin and agarotetrol.CONCLUSION We should pay attention to the unstable quality of Qishiwei Zhenzhu Pills.

2.
Chinese Traditional Patent Medicine ; (12): 2072-2076, 2017.
Artigo em Chinês | WPRIM | ID: wpr-657961

RESUMO

AIM To establish an HPLC method for the simultaneous content determination of six constituents in Tibetan medicine Qishiwei Zhenzhu Pills (Croci Stigma,Dalbergiae odoriferae Lignum,Glycyrrhizae Radix et Rhizoma,etc.).METHODS The analysis of 50% methanol extract of this drug was carried out on a 30 ℃ thermostatic Inertsil(C)ODS-3 column (250 mm ×4.6 mm,5 μm),with the mobile phase comprising of 0.2% phosphoric acid-acetonitrile flowing at 0.8 mL/min in a gradient elution manner,and the detection wavelength was set at 254 nm.RESULTS Gallic acid,corilagin,agarotetrol,ellagic acid,crocin Ⅰ and crocin Ⅱ showed good linear relationships within the ranges of 1.41-42.24,0.61-18.24,0.30-9.12,0.47-14.04,0.62-18.48 and 0.32-9.45 μg/mL (R2 ≥0.999 4),whose average recoveries (RSDs) were 93.41% (1.75%),96.84% (1.75%),97.45% (0.58%),93.22% (0.56%),97.01% (1.39%) and 97.22% (1.11%),respectively.The contents of various constituents in different batches of samples from two manufactures showed some differences,especially for those of corilagin and agarotetrol.CONCLUSION We should pay attention to the unstable quality of Qishiwei Zhenzhu Pills.

3.
Chinese Journal of Oncology ; (12): 747-750, 2013.
Artigo em Chinês | WPRIM | ID: wpr-267464

RESUMO

<p><b>OBJECTIVE</b>To investigate the correlation of baseline plasma D-dimer levels and clinicopathological features and tumor VEGF expression in non-small cell lung cancer(NSCLC) patients, and to evaluate the value of D-dimer in predicting survival time.</p><p><b>METHODS</b>A retrospective review of the clinicopathological data of 290 NSCLC patients confirmed pathologically in Tianjin Cancer Hospital from July 2007 to April 2009 was performed. The correlations between plasma baseline D-dimer levels and clinicopathological characteristics and progonosis were analyzed.</p><p><b>RESULTS</b>For 290 NSCLC patients with low ( ≤ 0.3 µg/ml) and high (>0.3 µg/ml) D-dimer levels, the median survival times were 54.0 months and 46.2 months, respectively (P < 0.05), and for the patients with stages I, II, IIIA, IIIB and IV NSCLC, the median survival times were 58.1, 40.6, 26.7 and 23.5 months, respectively (P < 0.05). In the operable patients (stages I, II and IIIa) with low and high D-dimer levels, the median progression-free survivals (PFS) were 35.0 and 11.0 months, respectively (P < 0.05). Furthermore, the median PFSs were 57.2 months and 19.6 months, respectively, in these operable patients without and with lymph node metastasis (P < 0.05).</p><p><b>CONCLUSIONS</b>High levels of baseline plasma D-dimer may indicate advanced disease stage, larger tumor size, lymph node metastasis and stronger tumor angiongenesis to some extent, and may be useful in prediction of survival time in NSCLC patients of different stages.</p>


Assuntos
Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Protocolos de Quimioterapia Combinada Antineoplásica , Usos Terapêuticos , Carcinoma Pulmonar de Células não Pequenas , Sangue , Tratamento Farmacológico , Patologia , Cirurgia Geral , Cisplatino , Usos Terapêuticos , Intervalo Livre de Doença , Produtos de Degradação da Fibrina e do Fibrinogênio , Metabolismo , Seguimentos , Neoplasias Pulmonares , Sangue , Tratamento Farmacológico , Patologia , Cirurgia Geral , Metástase Linfática , Estadiamento de Neoplasias , Paclitaxel , Pneumonectomia , Métodos , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Taxa de Sobrevida , Taxoides , Usos Terapêuticos , Carga Tumoral , Fator A de Crescimento do Endotélio Vascular , Metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA